La

Laekna

Shanghai CNFounded 201850 employees
Private CapbiotechPrivateOncology
Platform: PI3K/mTOR
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
LAE-3866LAE-3866Phase 1/21NanobodyFXIaBTKiFLEwing Sarcoma
BemaosocimabLAE-9406Phase 32Gene TherapyIL-17AGLP-1agRettNarcolepsy
LAE-436LAE-436Preclinical2Bispecific AbMETCl18.2WMMelanoma
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)
2025-02-06
LAE-436 Interim
WM
Past
2026-07-16
LAE-3866 Fast Track
Ewing Sarcoma
Fast Track
2027-10-14
Bemaosocimab Ph3 Readout
Rett
Ph3 Readout
2029-07-23
Bemaosocimab Ph3 Readout
Rett
Ph3 Readout
2030-08-15
LAE-3866 Ph2 Data
Ewing Sarcoma
Ph2 Data